公司概覽
業務類別 Diagnostics & Research
業務概覽 Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
公司地址 5200 Illumina Way, San Diego, CA, USA, 92122
電話號碼 +1 858 202-4500
傳真號碼 +1 858 202-4545
公司網頁 https://www.illumina.com
員工數量 10080
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Mr. Jacob Thaysen Director and Chief Executive Officer 美元 1.00M 09/04/2026
Mr. Ankur Dhingra Chief Financial Officer 美元 650.00K 09/04/2026
Mr. Kevin Carl Pegels Chief, Global Operations 美元 575.00K 09/04/2026
Mr. Scott Ericksen Vice President and Chief Accounting Officer -- 12/02/2026
Dr. Steve Barnard, PhD Chief Technology Officer 美元 600.00K 09/04/2026
Ms. Patricia Leckman Chief People Officer -- 09/04/2026
Mr. Christensen Jakob Wedel Chief Strategy and Corporate Development Officer -- 09/04/2026
Mr. Scott M. Davies Chief Legal Officer -- 09/04/2026
 
董事會成員
董事會 職務 更新日期
Ms. Caroline D. Dorsa Independent Director 09/04/2026
Ms. Anna S. Richo Independent Director 09/04/2026
Mr. David P King Independent Director 09/04/2026
Mr. Keith A. Meister Independent Director 09/04/2026
Mr. Philip W. Schiller Independent Director 09/04/2026
Ms. Susan E. Siegel Independent Director 09/04/2026
Dr. Scott Gottlieb,M.D. Chairman of the board 09/04/2026
Mr. Scott B. Ullem Independent Director 09/04/2026
Mr. Jacob Thaysen Director and Chief Executive Officer 09/04/2026
Dr. Daniel M. Skovronsky, M.D.,PhD Independent Director 23/06/2026
 
所屬ETF (更新日期: 14/11/2026 03:04)
代號 名稱 佔比% ▼ 持有日期
NXTISimplify Next Intangible Core Index ETF<0.000001%29/10/2026
ORRMilitia Long/Short Equity ETF<0.000001%07/10/2026
PAMCPacer Lunt MidCap Multi-Factor Alt ETF<0.000001%28/09/2026
PJFMPGIM Jennison Focused Mid-Cap ETF<0.000001%08/09/2026
PTMCPacer Trendpilot™ US Mid Cap ETF<0.000001%21/09/2026
QQJGInvesco ESG NASDAQ Next Gen 100 ETF<0.000001%20/02/2026
QVMMInvesco S&P MidCap 400 QVM Mlt-fctr ETF<0.000001%21/09/2026
RALSProShares RAFI® Long/Short<0.000001%30/04/2022
RWKInvesco S&P MidCap 400 Revenue ETF<0.000001%21/09/2026
SAGPStrategas Global Policy Opp ETF<0.000001%08/09/2026
SHEStt Strt® SPDR® MSCI USA Gndr Divst ETF<0.000001%27/08/2025
SMDXIntech S&P Small-Mid Cap Divers Alp ETF<0.000001%23/09/2026
SMOXHorizon Small/Mid Cap Core Equity ETF<0.000001%22/10/2026
SPMDState Street SPDR Port S&P 400 Md CpETF<0.000001%21/09/2026
SPXXNuveen S&P 500 Dynamic Overwrite<0.000001%30/09/2026
SSSCyber Hornet S&P 500®AndSol75/25StrETF<0.000001%30/10/2026
TGRTT. Rowe Price Growth ETF<0.000001%18/09/2026
UMDDProShares UltraPro MidCap400<0.000001%21/09/2026
USNZXtrackers Net Zero Pwy Par Alg US Eq ETF<0.000001%07/08/2025
WRNDNYLI Global Equity R&D Leaders ETF<0.000001%28/08/2025
  1    2    3    4    5    6    7    8    9    10    11    12    13    14    15    16    17   18    19  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.